Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.
Provider: Pechala's Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

IGI Laboratories Inc completes seventh ANDA filing for under joint drug development and commercialization agreement with Impax Laboratories, Inc.

Friday, 20 Jun 2014 08:00am EDT 

IGI Laboratories Inc:Submits its seventh abbreviated new drug application (ANDA) in 2014 to the U.S. Food and Drug Administration (FDA).Seventh ANDA submission was in connection with an existing development, supply and marketing agreement with Impax Laboratories, Inc.Agreement designates IGI Laboratories, Inc. (IGI) as developer, manufacturer, and owner of generic topical pharmaceutical drug product, which will be licensed, marketed and distributed in United States by Global Pharmaceuticals, Impax's generics division.In accordance with the agreement, Impax is required to pay IGI when certain milestones are met related to the filing and approval of the associated ANDA. 

Company Quote

0.13 +1.43%
26 Dec 2014